ES2032105T3 - Un metodo de preparacion de un compuesto que es un acido (cicloalquilamino) metilenbifosfonico. - Google Patents

Un metodo de preparacion de un compuesto que es un acido (cicloalquilamino) metilenbifosfonico.

Info

Publication number
ES2032105T3
ES2032105T3 ES198989300560T ES89300560T ES2032105T3 ES 2032105 T3 ES2032105 T3 ES 2032105T3 ES 198989300560 T ES198989300560 T ES 198989300560T ES 89300560 T ES89300560 T ES 89300560T ES 2032105 T3 ES2032105 T3 ES 2032105T3
Authority
ES
Spain
Prior art keywords
methylenbyphosphonic
cyclloalkylamine
preparing
compound
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198989300560T
Other languages
English (en)
Spanish (es)
Inventor
Yasuo Isomura
Makoto Takeuchi
Shuichi Sakamoto
Tetsushi Abe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2032105T3 publication Critical patent/ES2032105T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839Polyphosphonic acids
    • C07F9/3873Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025Esters of poly(thio)phosphonic acids
    • C07F9/405Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES198989300560T 1988-01-20 1989-01-20 Un metodo de preparacion de un compuesto que es un acido (cicloalquilamino) metilenbifosfonico. Expired - Lifetime ES2032105T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1165688 1988-01-20

Publications (1)

Publication Number Publication Date
ES2032105T3 true ES2032105T3 (es) 1993-01-01

Family

ID=11784011

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198989300560T Expired - Lifetime ES2032105T3 (es) 1988-01-20 1989-01-20 Un metodo de preparacion de un compuesto que es un acido (cicloalquilamino) metilenbifosfonico.

Country Status (14)

Country Link
US (2) US4970335A (enExample)
EP (1) EP0325482B1 (enExample)
KR (1) KR970005179B1 (enExample)
CN (1) CN1022630C (enExample)
AT (1) ATE74361T1 (enExample)
AU (1) AU615711B2 (enExample)
CA (1) CA1339805C (enExample)
DE (1) DE68901097D1 (enExample)
DK (1) DK174744B1 (enExample)
ES (1) ES2032105T3 (enExample)
GR (1) GR3004461T3 (enExample)
HU (1) HU202243B (enExample)
IE (1) IE60477B1 (enExample)
PH (1) PH26819A (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
IE912115A1 (en) * 1990-06-25 1992-01-01 Takeda Chemical Industries Ltd Bisphosphonic acid derivatives, their production and use
US5073339A (en) * 1990-08-23 1991-12-17 W. R. Grace & Co. - Conn Method of inhibiting corrosion and scale formation in aqueous systems
ATE133677T1 (de) * 1990-12-19 1996-02-15 Takeda Chemical Industries Ltd Bisphosphonsäurederivate, ihre produktion und ihre verwendung
EP0498424A1 (en) * 1991-02-07 1992-08-12 Kaken Pharmaceutical Co., Ltd. Bisphosphonic acid derivatives and bone resorption inhibitors containing them
CA2102303A1 (en) * 1991-06-19 1992-12-20 Roy Allen Johnson Dialkyl (dialkoxyphosphinyl) methyl phosphates as anti-inflammatory agents
EP0522576A3 (en) * 1991-07-12 1993-07-14 Hoechst Aktiengesellschaft Aminoethane-1,1-bisphosphonic acids and aminoethane-1,1-alkylphospinic/phosphonic acids, process of their preparation and their use
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
JPH11511041A (ja) 1995-06-06 1999-09-28 メルク エンド カンパニー インコーポレーテッド 整形外科的埋め込み装置の無菌性動揺を防止するビスホスホネートセメント組成物
US20030096760A1 (en) * 1997-03-10 2003-05-22 Smithklinebeecham Corporation Method of antagonizing the human SRC SH2 domain
IT1303672B1 (it) 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
KR20020059790A (ko) * 1999-11-25 2002-07-13 오노다 마사요시 치주병 치료제
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
CA2469779C (en) * 2001-12-21 2008-02-12 The Procter & Gamble Company Method for the treatment of bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
JP4502641B2 (ja) * 2002-01-24 2010-07-14 ティルタン ファーマ リミテッド 抗癌組み合わせおよびその使用方法
CN1939314A (zh) 2002-05-10 2007-04-04 弗·哈夫曼-拉罗切有限公司 用于治疗和预防骨质疏松症的二膦酸
US20060258726A1 (en) * 2002-06-06 2006-11-16 Xavier Billot 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
WO2004019938A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
SI1596870T2 (sl) * 2002-12-20 2011-07-29 Hoffmann La Roche Formulacija z visokim odmerkom ibandronata
AU2004266740B2 (en) 2003-08-21 2010-08-26 Merck Frosst Canada Ltd Cathepsin cysteine protease inhibitors
WO2005027921A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
PT2269584T (pt) 2004-05-24 2022-07-01 Theramex Hq Uk Ltd Forma de dosagem oral entérica sólida de um bisfosfonato contendo um agente quelante
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
SI1855674T1 (sl) 2005-03-02 2014-10-30 Merck Sharp & Dohme Corp. Sestavek za inhibicijo katepsina k
EA200701997A1 (ru) * 2005-03-17 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиция из наночастиц бисфосфоната
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
PT2222636E (pt) 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
US20090181138A1 (en) 2008-01-11 2009-07-16 David Howard Process for producing precooked bacon slices
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
EP3055314B1 (en) 2013-10-08 2018-09-12 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
PL407922A1 (pl) 2014-04-16 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Nowe bisfosfoniany i ich zastosowanie
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
MX2021012690A (es) 2019-04-19 2022-01-31 Ligand Pharm Inc Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1958123C3 (de) * 1969-11-19 1978-09-28 Henkel Kgaa, 4000 Duesseldorf Verfahren zur Herstellung von 1 -Aminoalkan-1,1 -diphosphonsäuren oder deren Salzen
DE2037586C3 (de) * 1970-07-29 1980-05-22 Henkel Kgaa, 4000 Duesseldorf Gipsmassen
DE2104476C2 (de) * 1971-02-01 1983-12-01 Henkel KGaA, 4000 Düsseldorf Verfahren zur Verhinderung von Ausfällungen in Wasser oder wäßrigen Lösungen
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
JPH01231980A (ja) * 1988-03-10 1989-09-18 Ishikawajima Harima Heavy Ind Co Ltd 管内作業用ピグ

Also Published As

Publication number Publication date
GR3004461T3 (enExample) 1993-03-31
DK174744B1 (da) 2003-10-13
US5041428A (en) 1991-08-20
DK24389A (da) 1989-07-21
KR890011601A (ko) 1989-08-21
EP0325482B1 (en) 1992-04-01
CN1035829A (zh) 1989-09-27
DK24389D0 (da) 1989-01-20
US4970335A (en) 1990-11-13
HUT50841A (en) 1990-03-28
CA1339805C (en) 1998-04-07
DE68901097D1 (de) 1992-05-07
KR970005179B1 (ko) 1997-04-14
EP0325482A1 (en) 1989-07-26
CN1022630C (zh) 1993-11-03
IE890183L (en) 1989-07-20
PH26819A (en) 1992-11-05
HU202243B (en) 1991-02-28
AU2867089A (en) 1989-07-20
IE60477B1 (en) 1994-07-13
AU615711B2 (en) 1991-10-10
ATE74361T1 (de) 1992-04-15

Similar Documents

Publication Publication Date Title
ES2032105T3 (es) Un metodo de preparacion de un compuesto que es un acido (cicloalquilamino) metilenbifosfonico.
DE3752257D1 (de) Verfahren zur Herstellung von 2-Arylpropionsäuren
PL239456A1 (en) Process for preparing derivatives of -arylalkanocarboxylic acids
MX9206083A (es) Metodos nuevos para la preparacion de esteres de cmetodos nuevos para la preparacion de esteres de carbonato de glicerol. arbonato de glicerol.
ATE166674T1 (de) Zusammensetzung und verfahren zur kesselstein- und korrosionsinhibierung, unter verwendung von naphtylaminpolykarbonsäuren
ES2147196T3 (es) Procedimiento para la hidrolisis estereoespecifica de derivados de piperidindiona.
ZA869080B (en) Process for the preparation of l-homoalanin-4-yl(methyl)-phosphinic acid and its alkyl esters
IT1196334B (it) Processo per la risoluzione ottica di miscugli racemi di acidi alfanaftil-propionici
GR3007465T3 (enExample)
MY101645A (en) Phosphoric esters and process for preparing the same.
ATE60580T1 (de) Verfahren zur herstellung von estern.
CA1267906C (en) PROSTAGLANDIN ANALOGS WITH 7-OXABICYCLOHEPTANE SUBSTITUTE
PT87901A (pt) Processo para a preparacao de acidos 2-ariloxipropionicos e de composicoes herbicidas contendo estes compostos
ES2059528T3 (es) Compuestos macrolidos.
PT89871A (pt) Processo para a preparacao de derivados de ester do acido ftalazinoacetico e de um novo intermediario
ATE309212T1 (de) Optisch aktive 1-phenylpyrrolidonderivate
DE69030884D1 (de) Verfahren zur herstellung von norbornan-sulfonamidderivat
DK161599C (da) Fremgangsmaade til fremstilling af lysergsyreestere

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 325482

Country of ref document: ES